Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
113,103,917
-
Share change
-
-452,454
-
Total reported value
-
$6,646,510,438
-
Put/Call ratio
-
91%
-
Price per share
-
$58.78
-
Number of holders
-
296
-
Value change
-
-$27,789,991
-
Number of buys
-
165
-
Number of sells
-
131
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q1 2024
As of 31 Mar 2024,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
296 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
113,103,917 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, EcoR1 Capital, LLC, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BlackRock Inc., T. Rowe Price Investment Management, Inc., JENNISON ASSOCIATES LLC, STATE STREET CORP, Octagon Capital Advisors LP, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
296
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.